KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Royalty Pharma (RPRX) Debt Ratio (2019 - 2025)

Historic Debt Ratio for Royalty Pharma (RPRX) over the last 7 years, with Q4 2025 value amounting to 0.46.

  • Royalty Pharma's Debt Ratio rose 920.47% to 0.46 in Q4 2025 from the same period last year, while for Dec 2025 it was 0.46, marking a year-over-year increase of 920.47%. This contributed to the annual value of 0.46 for FY2025, which is 920.47% up from last year.
  • Per Royalty Pharma's latest filing, its Debt Ratio stood at 0.46 for Q4 2025, which was up 920.47% from 0.46 recorded in Q3 2025.
  • In the past 5 years, Royalty Pharma's Debt Ratio registered a high of 0.46 during Q3 2025, and its lowest value of 0.36 during Q2 2021.
  • Its 5-year average for Debt Ratio is 0.41, with a median of 0.42 in 2022.
  • Per our database at Business Quant, Royalty Pharma's Debt Ratio tumbled by 1151.42% in 2023 and then soared by 1366.52% in 2025.
  • Quarter analysis of 5 years shows Royalty Pharma's Debt Ratio stood at 0.41 in 2021, then grew by 2.91% to 0.42 in 2022, then dropped by 11.51% to 0.37 in 2023, then rose by 11.54% to 0.42 in 2024, then rose by 9.2% to 0.46 in 2025.
  • Its last three reported values are 0.46 in Q4 2025, 0.46 for Q3 2025, and 0.44 during Q2 2025.